Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A

Trial Profile

Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms guardian-2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 03 Jul 2017 According to Novo Nordisk media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress 2017.
    • 06 Dec 2016 Interim results from guardian™2 trial (n=199) and on-demand subtrial (n=19) of turoctocog alfa, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 29 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top